Clinical Trial Update: ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of ABT-751 (E7070) in metastatic prostate cancer that progressed after hormone therapy; the trial was terminated with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ABT-751 (ABT-751)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-06-27